Nusaibah Al-Jaloudi’s Post

🚀 Breakthrough in Pharmaceutical Market Access Strategies! 🌍 In the rapidly evolving pharmaceutical landscape, market access is more critical than ever for the success of new treatments and innovations. As we navigate complex pricing strategies and regulatory pathways, understanding these dynamics is essential for ensuring that novel therapies reach patients efficiently. 🔍 Key Insights: - Value-Based Pricing: Aligning drug costs with clinical benefits enhances market penetration. - Regulatory Expertise: Navigating approval processes across regions is vital for compliance and expedited access. - Digital Solutions: Leveraging technology and data analytics streamlines market strategies. Collaboration among pharmaceutical companies, regulators, and healthcare providers is key to overcoming challenges in market access. Together, we can drive improvements in global health outcomes! 👉 Click the link to explore more about these transformative strategies! #DigitalHealth #HealthTechnologyAssessment #HealthcareInnovation #MarketAccess #Pharmaceuticals #Publications #ValueBasedPricing #MarketAccess #MarketAccessToday

PhRMA participated in the 2024 China Development Forum and submitted an Enterprise Paper covering “Biopharmaceutical Innovation: Fostering Research, Development and Patient Access.” The paper reviews past biopharmaceutical developments and proposes a series of policy recommendations. Enterprise Paper 2024 highlights: o Over the last decade, the global biopharmaceutical industry has more than doubled its annual investment, reaching $262 billion in 2023. o China's R&D pipeline has seen over 10-fold growth in preclinical and clinical developments in the past decade, promising a surge in innovative medicines in the coming years. o In the last 10 years, only 24% of new medicines launched globally are available in China, versus 85% in the US and 38% in OECD countries. Moreover, just 15% of global new medicines are reimbursed under China's National Reimbursement Drug List (NRDL). o An aging population and expectations for better health and longevity have accelerated the demand for health care in China. o Sustained growth of the biopharmaceutical sector will require a supportive policy environment to enable innovative medicines to reach patients and to incentivize continued research in the next generation of treatments and cures. o Innovative biopharmaceutical companies look for stable and predictable pro-innovation policy environments when making decisions regarding medicines development and launch. Such policies include: 1) strong intellectual property protection for innovations; 2) predictable, science-based regulatory pathways for timely market access; and 3) a payment system that rewards innovation and enables further investment in the next generation of medicines. Biopharmaceutical innovation is transforming how we diagnose, treat, cure, and prevent disease, improving lives across a wide range of conditions. With the right policy environment, we can maximize the potential of these innovations, ensuring patients live healthier, longer lives. To dive deeper into our findings and policy suggestions, read the full Enterprise Paper here: https://lnkd.in/gWCg-HiZ #PharmaceuticalInnovation #ChinaDevelopmentForum #Biopharma #HealthcareTransformation #InnovationPolicy

Part 2: The Conflict of Interest in Drug Research: The Challenge of Incentives in Clinical Services Partnerships The landscape of pharmaceutical research and development is deeply entrenched in a complex web of partnerships and collaborations. However, a critical issue that often goes unnoticed is the misalignment of incentives within the clinical research ecosystem, particularly among Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and other key clinical services companies. The core of this issue lies in the lack of incentive for these partners to optimize the efficiency and accuracy of drug trials, as doing so may directly impact their revenues. The perpetuation of prolonged and less nimble research not only results in inflated costs but also poses a significant hurdle in getting life-saving medications to patients in need swiftly and efficiently. This presents a formidable barrier to the pursuit of streamlined and agile drug development, impacting both the industry's ability to innovate and the timely delivery of critical treatments. In light of the stark contrast in stock performance between Thermo Fisher Scientific (TMO) and Pfizer (PFE) over the past 20 years, where TMO showcased a striking 2000% increase while PFE experienced a consequential 25% decrease, the need for a shift in the incentives and partnerships becomes even more apparent. It is imperative to acknowledge that the ability to leverage objective medication adherence data insights is a crucial differentiator in this disparity. Companies like Information Mediary Corp, striving to transform clinical research with their smart packaging-based adherence insights, face the challenge of a misaligned partnership landscape that limits the widespread adoption of transformative technologies. It is time to initiate a dialogue that challenges the status quo and encourages a redefined partnership model—an approach that aligns the interests of all parties involved. This paradigm shift calls for a collaborative effort to cultivate a culture of shared value and innovative solutions in drug research partnerships. By doing so, we can pave the way for a future where efficiency and impact align seamlessly, driving substantial advancements in drug development. The pharmaceutical industry stands at a crucial juncture, demanding a pivotal shift in the dynamics between research teams and their clinical services partners. Let's strive for a future where the pursuit of efficiency and impact is mutually beneficial, revolutionizing the landscape of drug development. This is our opportunity to carve a new path—a path unencumbered by conflicting interests and fueled by the promise of collaborative success in drug research. The graph speaks for itself. #cfo #clincialtrial #drugdevelopment #medicationadherence

In the rapidly evolving pharmaceutical industry, one strategy is transforming how companies operate and thrive globally. Regionalization drives innovation, agility, and market success. Want to know more about the key strategies and success stories of industry giants like Novartis, Roche, and AstraZeneca? Click to read more and stay ahead in the competitive landscape! https://lnkd.in/d8y5nY7D #Pharmaceuticals #Innovation #Regionalization #Healthcare #MarketStrategy #PharmaInsights

🌟 Professor Cookson Champions Value-Based Drug Pricing in Belgium! 🇧🇪💊 In a pivotal address to the Belgian House of Representatives, Professor Graham Cookson, Chief Executive of OHE, advocated for a transformative value-based approach to drug pricing. 🔍 Key Highlights: - Fair Pricing Mechanisms: Proposed bills aim for objective pricing and transparent criteria for pharmaceuticals. - Sustainable Healthcare Funding: Aligning prices with patient and societal priorities ensures effective innovations are accessible. - Revolutionizing the Pharmaceutical Sector: A value-based model can balance patient access with economic sustainability. This approach not only incentivizes high-quality medication development but also directs investments towards drugs that truly benefit society. 👉 Click the link to learn more about how this strategy could serve as a model for countries worldwide facing similar challenges! #Belgium #HealthEconomics #HealthcareInnovation #Pharmaceuticals #PricingandReimbursement #Publications #RegulatoryAgencies #SustainableHealthcare #ValueBasedPricing #MarketAccess #MarketAccessToday

🌟 EUCOPE Welcomes New Commissioners to Propel Pharma Innovation in Europe! 🌟 In a pivotal moment for the pharmaceutical landscape, EUCOPE extends its congratulations to the newly appointed European Commissioners. Their leadership is essential for enhancing innovation and competitiveness within the EU's pharmaceutical sector. 🔑 Key Highlights: - Strengthened collaboration among small and mid-sized firms is set to drive significant innovation. - The implementation of the EU Rare Disease Framework will streamline orphan drug development. - Continued investment in research infrastructure is critical for maintaining Europe’s leadership in medical advancements. As emphasized by Alexander Natz, Secretary General of EUCOPE, a robust pharmaceutical ecosystem is vital for ensuring timely access to cutting-edge treatments across Europe. 📈 By prioritizing an innovation-centric approach, we can spur economic growth while delivering superior health outcomes. EUCOPE remains committed to partnering with the new Commission as we tackle future challenges together! 👉 Click on the link for more insights! #EUCOPEStrategy #HealthcareLeadership #MedicalAdvancements #OrphanDrugs #Pharma #PharmaInnovation #RegulatoryAgencies #MarketAccess #MarketAccessToday

Optimizing Entry Strategies for Spanish Pharma in the MENA Region 💡 Discover effective market entry strategies for Spanish pharmaceutical companies aiming to expand into the MENA region. This blog covers the importance of comprehensive market research, building strategic local partnerships, and navigating regulatory requirements. Learn about adapting products to local needs, leveraging digital tools, and overcoming common challenges such as cultural and language barriers. The article emphasizes the significance of continuous monitoring and strategy adjustment to ensure long-term success in the MENA market. #MENA_pharmaceutical_market #Spanish_pharma_market_entry #Healthcare_investments_in_MENA #Strategic_local_partnerships #Regulatory_compliance_MENA #Market_research_for_pharma #Digital_tools_in_pharma #Local_product_adaptation

The 2024 Access to Medicine Index is here and the rankings are making waves.   For the first time ever, Novartis takes the top spot, displacing GSK, the long-time leader, now in second place. Sanofi, meanwhile, makes a bold entry into the top three. The Index evaluates 20 of the world’s largest pharmaceutical companies on their efforts to improve access to medicines, vaccines, and diagnostics in low- and middle-income countries (LMICs). While some companies are stepping up, the 2024 results show overall progress remains slow. Here are the highlights: 1️⃣ Novartis (1st) and GSK (2nd) are top performers across all three areas: Governance of Access, R&D and Product Delivery.  2️⃣ Sanofi (3rd), Pfizer (4th), AstraZeneca (Joint 5th), Johnson & Johnson (Joint 5th) are four high performers.  3️⃣ Boehringer Ingelheim (8th) joins the top 10 for the first time, driven by strong capacity-building initiatives.  4️⃣ Companies like Gilead Sciences and MSD lag at the 16th spot due to gaps in Governance and R&D. Despite some shifts, the Index highlights significant challenges: - Only 43% of clinical trials occur in the 113 LMICs analysed, leaving many underserved regions behind. - Momentum in voluntary licensing has slowed, with limited new agreements. - Access gaps in low-income countries remain persistent. Pharmaceutical companies have the power to transform global healthcare. The question is: Are they doing enough to reach the people who need them the most? It’s time for decisive action. Greater focus on inclusive business models, increased clinical trial representation in underserved regions and expanded voluntary licensing can make a world of difference. Let’s keep pushing for progress. PS: Which part of the Index findings stood out to you the most? For further information and to download the full report: https://lnkd.in/esZ_cphD #GlobalHealth #AccessToMedicine  #PharmaInnovation #HealthcareEquity Access to Medicine Foundation ♻️ If this topic resonates with you, repost to amplify awareness. 🔔 Follow Anna Dé for more insights on global health policy matters.

Want to know what has underpinned Mainland China’s impressive growth into a global #pharmaceuticals superpower? This new (free to download) report identifies key policy decisions of the past decade and looks at the prospects for the next ten years as it continues its transition from “made in China” to “created in China”

Discover how Mainland China has transformed into a global biopharmaceutical powerhouse! Our latest report dives deep into the key policy decisions, innovative strides, and groundbreaking advancements that have fueled this remarkable journey. Don't miss out on these insights. #PharmaceuticalInnovation #BiopharmaLeadership #HealthcareRevolution #GlobalHealth #MedicalAdvancements #LifeSciences #Biotech #FutureOfMedicine #HealthTech #InnovationInHealthcare #China